The results of this study further confirm the role of genetic variability in dopaminergic pathway in the development of AEs of dopaminergic treatment in PD and suggest some new possible predictive biomarkers of the studied AEs, such as COMT rs165815 and SLC22A1 rs628031. The gene discussed is SLC22A1; the disease is Parkinson disease.